Therapeutic Effect of Nanobots in the Treatment of Joint Diseases

Project Information

OrthoBots

Grant agreement ID: 101189423

DOI

10.3030/101189423

Project closed

EC signature date 23 July 2024

Start date 1 November 2024

End date 30 April 2026

Funded under

• European Research Council (ERC)

Total cost

No data

EU contribution

€ 150 000,00

Coordinated by

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
Spain

Periodic Reporting for period 1 - OrthoBots (Therapeutic Effect of Nanobots in the Treatment of Joint Diseases)

Reporting period: 2024-11-01 to 2026-04-30

Summary of the context and overall objectives of the project

Osteoarthritis and degenerative joint diseases represent a massive and growing healthcare challenge, affecting millions of citizens and placing a significant economic burden on healthcare systems. A major hurdle in treating these conditions is the unique, dense structure of cartilage. Cartilage lacks a direct blood supply, making it notoriously difficult for traditional drugs to penetrate and reach the damaged cells. Currently, therapeutics injected into the joint cavity are rapidly cleared, resulting in poor efficacy, the need for frequent painful injections, and primarily palliative care rather than true disease modification. The OrthoBots project addresses this critical clinical gap by leveraging ground-breaking nanomotor technology. Rather than relying on the passive diffusion of drugs, OrthoBots utilizes biocompatible, self-propelling nanorobots. These nanometric vehicles are designed to actively navigate through the synovial fluid and penetrate deep into the dense matrix of the cartilage. By actively swimming to the site of damage, OrthoBots can deliver therapeutic agents directly to the targeted cells. This active delivery mechanism significantly enhances drug retention time, maximizes therapeutic efficacy, and minimizes unwanted systemic side effects. The project achieved several critical milestones essential for clinical translation. The project successfully demonstrated the functional capabilities of the nanobots in physiologically relevant models, validating their mobility, deep tissue penetration, and safety profile in targeting cartilage tissue. Navigating the translation of nanotechnology into the clinic requires strict adherence to medical guidelines. The team established a comprehensive regulatory roadmap, clarifying the classification of the OrthoBots platform and defining the exact pre-clinical and clinical steps required for future European regulatory approval. Moreover, a deep analysis of the orthopedic market was conducted, alongside extensive engagement with clinical key opinion leaders. This validated the immense clinical need and market appetite for technology. Consequently, a robust business plan was developed to guide the commercialization process.

During the Proof of Concept phase, the OrthoBots project advanced simultaneously across three main pillars: technical validation, regulatory planning, and commercial strategy. The objective was to elevate the technology from a laboratory-proven concept to a viable, market-ready medical innovation. The core scientific work focused on optimizing the design and functionality of the biocompatible nanorobots. The team successfully fabricated these nanoscopic vehicles and adapted them to operate effectively within the highly viscous environment of human joints. Through rigorous laboratory testing using both synthetic and biological models, the project achieved its primary technical milestone: demonstrating that these active nanorobots can self-propel through synovial fluid and successfully penetrate deep into the dense, complex matrix of cartilage tissue. This proved the fundamental concept that active delivery can overcome the physical barriers that currently limit traditional orthopedic treatments. Translating cutting-edge nanotechnology into clinical practice requires strict adherence to medical safety standards. To bridge the gap between research and the clinic, the team collaborated with external regulatory experts to develop a comprehensive roadmap. This work successfully identified the precise classification of the OrthoBots technology under current European regulatory frameworks for medical devices and combination products. The resulting strategy outlines a clear, step-by-step pathway, detailing the required pre-clinical safety protocols, manufacturing quality standards, and future clinical trial designs needed to secure European regulatory approval for human use eventually. Parallel to the scientific and regulatory advancements, the project laid a strong foundation for future commercial exploitation. The team conducted an in-depth analysis of the orthopedic market, focusing specifically on the massive clinical need surrounding osteoarthritis and joint degradation. By engaging in extensive interviews with key opinion leaders, orthopedic surgeons, and industry stakeholders, the project gathered vital real-world feedback.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The current clinical standard for treating degenerative joint diseases, such as osteoarthritis, relies on intra-articular injection of therapeutic agents into the synovial cavity. However, the avascular and highly dense nature of cartilage severely limits drug transport, forcing therapies to depend on passive diffusion. As a result, most compounds are rapidly cleared from the joint before reaching deep chondrocyte populations, providing only short-term symptomatic relief. OrthoBots addresses this fundamental limitation by introducing active, targeted delivery through self-propelling, biocompatible nanobots. Rather than relying on diffusion, these nano-vehicles harness the local joint environment to actively navigate the viscous synovial fluid and penetrate the dense cartilage matrix. A key outcome of the project was demonstrating that this active delivery strategy is feasible in physiologically relevant conditions. Synovial fluid, a highly viscous medium that normally restricts particle motion, was successfully traversed by the engineered nanorobots through autonomous propulsion. Likewise, despite the compact, sponge-like architecture of cartilage with nanoscale porosity, the nanobots were able to infiltrate deeply into the tissue. This active transport mechanism enabled efficient delivery of therapeutic cargo directly to chondrocytes embedded within the cartilage, significantly outperforming conventional passive injection approaches in terms of penetration depth, targeting precision, and retention time.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The OrthoBots project addresses osteoarthritis and degenerative joint diseases, which are among the most prevalent and debilitating conditions globally. By offering a transformative, nanorobotic approach to treating cartilage degradation, the expected impacts span deep societal benefits and significant economic savings. Osteoarthritis causes chronic pain and a progressive loss of mobility, severely impacting patients’ independence and mental health. Current standard-of-care treatments are largely palliative, offering only temporary pain relief. By actively delivering therapeutics deep into the cartilage to modify the disease and promote actual tissue regeneration, OrthoBots aims to restore joint function. This will allow patients to maintain their mobility, active lifestyles, and overall well-being for much longer. The economic toll of joint diseases is staggering. Costs are driven by frequent clinical visits for recurring injections, long-term pain management medications, and the eventual need for highly invasive, exceptionally expensive total joint replacement surgeries. Because the OrthoBots technology maximizes drug retention and efficacy within the joint, it promises to drastically reduce the frequency of patient hospital visits. Furthermore, by halting or reversing disease progression, it could delay or eliminate the need for joint replacements, offering massive long-term financial relief to overburdened European healthcare systems. While the socio-economic promise of OrthoBots is immense, translating a breakthrough from the laboratory to the hospital is a highly rigorous process. Before this technology can safely transition into human clinical trials, further extensive research at the laboratory scale is required. The immediate next phase will involve critical pre-clinical testing using advanced animal models. These vital studies are necessary to definitively confirm long-term safety, optimize dosages, and thoroughly evaluate the body’s biological response over time. Only after passing these stringent, mandatory pre-clinical milestones can the OrthoBots technology safely take the final leap into the clinic to benefit human patients.